Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net income	$ 34,410	$ 27,699
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,825	3,894
Net (accretion) amortization of (discounts) premiums on securities	(2,235)	1,456
Provision (benefit) for credit losses	5,490	(3,415)
Share-based compensation	1,460	1,315
Deferred income tax expense	843	2,384
Proceeds from sale of loans held for sale	16,049	19,920
Originations of loans held for sale	(15,868)	(20,437)
Income on company owned life insurance	(5,742)	(2,658)
Net gain on sale of loans held for sale	(257)	(212)
Net gain on sale or call of investment securities	(3)	0
Net gain on sale of assets of subsidiary	0	(13,520)
Net loss on sale of other assets	0	25
Decrease in other assets	15,854	10,134
(Decrease) increase in other liabilities	(49,546)	21,379
Net cash provided by operating activities	4,280	47,964
Cash flows from investing activities:
Purchases of available for sale securities	(93,434)	(124,748)
Purchases of held to maturity securities	(2,045)	(762)
Proceeds from principal payments, maturities and calls on available for sale securities	40,833	130,587
Proceeds from principal payments, maturities and calls on held to maturity securities	25,868	20,527
Proceeds from sales of available for sale securities	64,955	0
Net increase in loans	(63,217)	(3,572)
Purchase of company owned life insurance, net	(72,905)	(12)
Proceeds received from surrender of company owned life insurance	73,958	0
Proceeds from sale of assets of subsidiary	0	27,000
Purchases of premises and equipment	(2,412)	(2,125)
Net cash (used in) provided by investing activities	(28,399)	46,895
Cash flows from financing activities:
Net increase (decrease) in deposits	51,283	(79,591)
Net increase in short-term borrowings	2,000	17,000
Repayment of long-term borrowings	(10,000)	0
Purchases of common stock for treasury	(481)	(396)
Cash dividends paid to common and preferred shareholders	(12,970)	(9,967)
Net cash provided by (used in) financing activities	29,832	(72,954)
Net increase in cash and cash equivalents	5,713	21,905
Cash and cash equivalents, beginning of period	87,321	124,442
Cash and cash equivalents, end of period	$ 93,034	$ 146,347